Results 41 to 50 of about 41,377 (182)

Efficacy and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in treatment of patients with chronic hepatitis C in the Republic of Srpska: A real-life study [PDF]

Scripta Medica, 2019
Background: The purpose of this study was to assess the antiviral efficacy and safety of the direct-acting antivirals (DAAs) in therapy of chronic hepatitis C virus (HCV) infection.
Verhaz Antonija, Kezić Zdravka, Stojiljković Miloš P., Škrbić Ranko   +3 more
doaj  

The Effects of Compulsory Licensing: A Case Study of HIV Drugs

Health Economics, EarlyView.
ABSTRACT Compulsory licensing is a legal mechanism that allows governments the use of patented medicines without the owner's consent, subject to conditions and compensation, to meet public‐health needs. Despite its policy relevance and increasing use, empirical evidence on its market effects remains limited.
Nicolau Martin‐Bassols, Miquel Serra‐Burriel, Kerstin Noelle Vokinger   +2 more
wiley   +1 more source

Ritonavir-Mediated Induction of Apoptosis in Pancreatic Cancer Occurs via the RB/E2F-1 and AKT Pathways

Pharmaceuticals, 2014
Recent observations suggest a lower incidence of malignancies in patients infected with HIV during treatment with Highly Active Anti-Retroviral Therapy (HAART) utilizing protease inhibitors.
Ramesh B. Batchu, Oksana V. Gruzdyn, Christopher S. Bryant, Aamer M. Qazi, Sanjeev Kumar, Sreedhar Chamala, Shu T. Kung, Ramana S. Sanka, Udaya S. Puttagunta, Donald W. Weaver, Scott A. Gruber   +10 more
doaj   +1 more source

A real‐world analysis of AI chatbot performance for medicines information enquiries

Journal of Pharmacy Practice and Research, EarlyView.
Abstract Background The provision of medicines information (MI) services requires interpretation and clinical judgement of complex scenarios by pharmacists. To date, few studies have assessed the performance of artificial intelligence (AI) chatbots to assist pharmacists providing MI advice.
Duncan Yorkston, Tracey Borrie, Paul Chin   +2 more
wiley   +1 more source

From nature to nanoscale: advances, challenges, and preclinical translation of nanofiber drug delivery systems containing plant‐derived active ingredients

Journal of the Science of Food and Agriculture, EarlyView.
Abstract Since the early 1960s, nanotechnology has been a critical area of science, allowing for the development of sophisticated nanomaterials. Nanofibers, one of the most widely used nanotechnological drug delivery systems, have emerged as a highly versatile platform within modern pharmaceutical sciences.
Heybet Kerem Polat, Yasin Turanlı, Nihat Kurt, Sefa Gözcü, Emre Tunçel, Hilal Bacanak, Eren Aytekin, Sedat Ünal   +7 more
wiley   +1 more source

Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong

Emerging Infectious Diseases
We compared the effectiveness and interactions of molnupiravir and nirmatrelvir/ritonavir and 2 vaccines, CoronaVac and Comirnaty, in a large population of inpatients with COVID-19 in Hong Kong. Both the oral antiviral drugs and vaccines were associated
Yue Yat Harrison Cheung, Eric Ho Yin Lau, Guosheng Yin, Yun Lin, Benjamin J. Cowling, Kwok Fai Lam   +5 more
doaj   +1 more source

Nirmatrelvir/ritonavir treatment in SARS-CoV-2 positive kidney transplant recipients – a case series with four patients

BMC Nephrology, 2023
Background Despite vaccination coronavirus disease 2019 (COVID-19)-associated mortality caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains high in kidney transplant recipients.
Johanna Schneider, Rika Wobser, Wolfgang Kühn, Dirk Wagner, Yakup Tanriver, Gerd Walz   +5 more
doaj   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Human papillomavirus persistence and clearance in women living with HIV: A five‐year retrospective analysis from an Italian university center

Acta Obstetricia et Gynecologica Scandinavica, EarlyView.
In women living with HIV, HPV clearance occurred after a mean of approximately 2 years under antiretroviral therapy. Baseline positivity for the high‐risk HPV pool was associated with delayed clearance, suggesting that HPV genotype may influence viral persistence more than immunovirological status in clinically stable patients.
Annunziata Carlea, Dario Colacurci, Giorgia D'Apice, Laura Letizia Mazzarelli, Massimiliano Pellicano, Luigi Falco, Ginevra Sepe, Oriana Imperatore, Giuseppe Maria Maruotti, Maurizio Guida, Laura Sarno   +10 more
wiley   +1 more source

In-vitro effects of protease inhibitors on BAX, BCL-2 and apoptosis in two human breast cell lines (with corrigendum)

South African Journal of Science, 2015
Currently, the treatment of choice of HIV/AIDS in South Africa is the multidrug combination regimen known as HAART (highly active antiretroviral treatment).
Gbenga A. Adefolaju, Katherine E. Theron, Margot J. Hosie   +2 more
doaj   +1 more source